Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO4929097 + Vismodegib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO4929097 | RG-4733 | Gamma secretase inhibitor 13 | RO4929097 (RG-4733) is a gamma secretase inhibitor, which blocks Notch cleavage and activation, and may inhibit angiogenesis and tumor growth (PMID: 19773430, PMID: 31953695). | |
Vismodegib | Erivedge | GDC-0449 | SMO Inhibitor 16 | Erivedge (vismodegib) binds to and inhibits Smoothened (SMO), resulting in inhibition of downstream signaling and decreased tumor growth (PMID: 24259609, PMID: 19716296). Erivedge (vismodegib) is FDA approved for use in patients with basal cell carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01154452 | Phase Ib/II | Vismodegib RO4929097 + Vismodegib RO4929097 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | Completed | USA | 0 |